Innovent Biologics Takes in $150 million in Series E Round - May Drop U.S. IPO Plans

Innovent Biologics, Inc., announced the completion of its US$150 million Series E round financing.  

This round of financing attracted high quality global institutional investors and biotech-focused funds.  Capital Group Private Markets (CGPM) is part of U.S.-based Capital Group Companies, one of the world's largest and most successful investment organizations, and led this round with a US$90 million investment. Nick Chen, Partner of CGPM, joined Innovent's Board of Directors.